These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30214852)

  • 1. Structural Basis for the Inhibition of Cyclin G-Associated Kinase by Gefitinib.
    Ohbayashi N; Murayama K; Kato-Murayama M; Kukimoto-Niino M; Uejima T; Matsuda T; Ohsawa N; Yokoyoma S; Nojima H; Shirouzu M
    ChemistryOpen; 2018 Sep; 7(9):721-727. PubMed ID: 30214852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
    Tabara H; Naito Y; Ito A; Katsuma A; Sakurai MA; Ohno S; Shimizu H; Yabuta N; Nojima H
    PLoS One; 2011; 6(10):e26034. PubMed ID: 22022498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
    Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
    PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
    Neveu G; Ziv-Av A; Barouch-Bentov R; Berkerman E; Mulholland J; Einav S
    J Virol; 2015 Apr; 89(8):4387-404. PubMed ID: 25653444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies.
    Chaikuad A; Keates T; Vincke C; Kaufholz M; Zenn M; Zimmermann B; Gutiérrez C; Zhang RG; Hatzos-Skintges C; Joachimiak A; Muyldermans S; Herberg FW; Knapp S; Müller S
    Biochem J; 2014 Apr; 459(1):59-69. PubMed ID: 24438162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
    Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
    Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
    Ahn SH; Jeong EH; Lee TG; Kim SY; Kim HR; Kim CH
    Cell Oncol (Dordr); 2014 Oct; 37(5):377-86. PubMed ID: 25228008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
    N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
    Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cyclin G-associated kinase (GAK) inhibitor SGC-GAK-1 inhibits neurite outgrowth and synapse formation.
    Egawa J; Arta RK; Lemmon VP; Muños-Barrero M; Shi Y; Igarashi M; Someya T
    Mol Brain; 2022 Jul; 15(1):68. PubMed ID: 35883152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
    Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
    Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.